UK regulator suspends Amgen’s Tavneos for new patients
Britain’s medicines regulator suspended the use and sale of Amgen’s rare-disease drug Tavneos to new patients, saying the main study supporting its approval was unreliable.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.